Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Superficial Bladder Urothelial Carcinoma”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Large-scale testing (Phase 3)Study completedNCT00445601
What this trial is testing

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
SWOG Cancer Research Network 406
Early research (Phase 1)Study completedNCT00001381
What this trial is testing

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Who this might be right for
Bladder NeoplasmsCarcinoma, Transitional Cell
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT00393809
What this trial is testing

Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer

Who this might be right for
Bladder Neoplasms
Hebrew University of Jerusalem 18
Testing effectiveness (Phase 2)UnknownNCT05495724
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Who this might be right for
Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 176
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06770582
What this trial is testing

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Who this might be right for
Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8
National Cancer Institute (NCI) 160
Large-scale testing (Phase 3)Ended earlyNCT00384891
What this trial is testing

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Who this might be right for
Urinary Bladder DiseasesUrinary Bladder NeoplasmsUrinary Bladder Cancer+5 more
Medical Enterprises Europe B.V. 190
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Early research (Phase 1)Looking for participantsNCT06766266
What this trial is testing

Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

Who this might be right for
Non-Muscle Invasive Bladder Urothelial Carcinoma
First Affiliated Hospital of Chongqing Medical University 18
Large-scale testing (Phase 3)WithdrawnNCT07342517
What this trial is testing

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc.
Not applicableLooking for participantsNCT06396533
What this trial is testing

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Who this might be right for
Urothelial CarcinomaMuscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
Fox Chase Cancer Center 92
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Study completedNCT00004122
What this trial is testing

BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Who this might be right for
Bladder Cancer
Roswell Park Cancer Institute
Early research (Phase 1)Study completedNCT01878188
What this trial is testing

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Who this might be right for
Transitional Cell Carcinoma of Bladder
Anchiano Therapeutics Israel Ltd. 38
Large-scale testing (Phase 3)Not Yet RecruitingNCT07464145
What this trial is testing

NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc. 393
Not applicableUnknownNCT05276167
What this trial is testing

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Who this might be right for
High-Risk, Non-Muscle Invasive Bladder Urothelial CarcinomaPerfusion; ComplicationsIntraoperative Complications
Henan Cancer Hospital 40
Not applicableUnknownNCT00126958
What this trial is testing

Cost-Effectiveness in Bladder Cancer

Who this might be right for
Bladder Cancer
Erasmus Medical Center 500
Early research (Phase 1)Looking for participantsNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 30
Large-scale testing (Phase 3)UnknownNCT00003725
What this trial is testing

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Who this might be right for
Bladder Cancer
Anthra Pharmaceuticals 300
Testing effectiveness (Phase 2)Study completedNCT00088946
What this trial is testing

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Who this might be right for
Bladder Cancer
Jonsson Comprehensive Cancer Center 17
Load More Results